Intelligence Feed event · Equity · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Direct answer

    Late-stage siRNA drug developer ADARx Pharmaceuticals successfully priced its initial public offering at $17.00 per share, upsizing the issue to 26.25 million shares. With trading initiating on September 25, 2026, the $446.3 million float tests capital market receptivity for clinical RNA therapeutics.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-initial-public-offering-at-17-697de7

    EQUITY
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    Late-stage siRNA drug developer ADARx Pharmaceuticals successfully priced its initial public offering at $17.00 per share, upsizing the issue to 26.25 million shares. With trading initiating on September 25, 2026, the $446.3 million float tests capital market receptivity for clinical RNA therapeutics.
    ADRX
    Impact
    66
    SEP 25
    SIG
    95%
    ADRX
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    Late-stage siRNA drug developer ADARx Pharmaceuticals successfully priced its initial public offering at $17.00 per share, upsizing the issue to 26.25 million shares. With trading initiating on September 25, 2026, the $446.3 million float tests capital market receptivity for clinical RNA therapeutics.
    → New equity issuance brings $446.3M in primary biotech liquidity to Nasdaq, setting pricing reference for clinical-stage RNA assets.
    Impact
    Late-stage siRNA drug developer ADARx Pharmaceuticals successfully priced its initial public offering at $17.00 per share, upsizing the issue to 26.25 million shares. With trading initiating on September 25, 2026, the $446.3 million float tests capital market receptivity for clinical RNA therapeutics.
    Affected
    ADRX
    Transmission
    New equity issuance brings $446.3M in primary biotech liquidity to Nasdaq, setting pricing reference for clinical-stage RNA assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXnasdaq public listing price discovery and liquidity injectionUpintradayADARx Pharmaceuticals priced its upsized IPO at $17 per share for $446.3M gross proceeds.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXUpdisagreed19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month